Jevtana Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.